Alterity Therapeutics Ltd Stock Australian S.E.
Stocks
AU000000PBT9
Biotechnology & Medical Research
OTC Markets Traded| Market Cap | 60.6M 54.14M 50.51M 45.88M 86.41M 5.86B 87.06M 607M 237M 2.98B 227M 223M 9.58B | P/E 2027 * |
-3.71x | P/E 2028 * | -0.35x |
|---|---|---|---|---|---|
| Enterprise Value | 50.64M 45.25M 42.22M 38.35M 72.22M 4.9B 72.76M 507M 198M 2.49B 190M 186M 8.01B | EV / Sales 2027 * |
46.7x | EV / Sales 2028 * | 12.1x |
| Free-Float |
97.02% | Yield 2027 * |
-
| Yield 2028 * | - |
Last Transcript: Alterity Therapeutics Ltd
| 1 day | +2.04% |
| Manager | Title | Age | Since |
|---|---|---|---|
David Stamler
CEO | Chief Executive Officer | 65 | 2021-01-06 |
| Director of Finance/CFO | - | 2024-09-29 | |
| Chief Tech/Sci/R&D Officer | - | 2019-03-31 |
| Director | Title | Age | Since |
|---|---|---|---|
Peter Marks
BRD | Director/Board Member | 70 | 2005-07-28 |
Lawrence Gozlan
BRD | Director/Board Member | 47 | 2011-08-07 |
David Stamler
BRD | Director/Board Member | 65 | 2025-11-20 |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +2.04% | +2.08% | - | - | 60.6M | |
| +4.16% | +4.16% | +49.37% | +94.17% | 74.68B | |
| -14.74% | -14.85% | +4.28% | +53.45% | 58.7B | |
| -1.94% | +1.11% | +4.04% | +32.12% | 48.36B | |
| -7.97% | -9.38% | +290.17% | +632.55% | 43.05B | |
| -1.76% | -2.23% | +27.07% | +27.75% | 42.48B | |
| -5.99% | -3.33% | -1.22% | +100.72% | 41.39B | |
| -0.11% | +1.96% | +9.19% | +52.66% | 31.29B | |
| -2.81% | -3.62% | -12.17% | -14.61% | 23.93B | |
| -4.03% | -9.49% | -39.26% | +300.98% | 22.22B | |
| Average | -3.30% | -2.18% | +36.83% | +142.20% | 42.9B | |
| Weighted average by Cap. | -3.80% | -1.56% | +43.64% | +135.43% |
| 2027 * | 2028 * | |
|---|---|---|
| Net sales | 1.08M 968K 903K 821K 1.55M 105M 1.56M 10.86M 4.24M 53.31M 4.07M 3.98M 171M | 1.95M 1.75M 1.63M 1.48M 2.79M 189M 2.81M 19.57M 7.65M 96.11M 7.33M 7.18M 309M |
| Net income | -27.31M -24.4M -22.77M -20.68M -38.95M -2.64B -39.24M -274M -107M -1.34B -103M -100M -4.32B | -30.69M -27.42M -25.59M -23.24M -43.77M -2.97B -44.1M -307M -120M -1.51B -115M -113M -4.85B |
| Net Debt | -9.95M -8.89M -8.3M -7.54M -14.19M -963M -14.3M -99.7M -38.95M -490M -37.37M -36.56M -1.57B | -36.93M -33M -30.79M -27.96M -52.67M -3.57B -53.06M -370M -145M -1.82B -139M -136M -5.84B |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
